Icahn Partners to nominate five to Amylin Pharmaceuticals board

By Angela McDaniels

Tacoma, Wash., Jan. 29 - Amylin Pharmaceuticals, Inc. investors led by Icahn Partners Master Fund LP and including Carl Icahn plan to nominate a slate of five directors to the company's board and to solicit proxies in favor of that slate, according to a schedule 13D/A filing with the Securities and Exchange Commission.

The investors said they have had conversations with Amylin concerning board representation without reaching an agreement.

The investors beneficially own 11,426,157 shares, or 8.3%, of the company's common stock.

Amylin confirmed in a news release that it reviewed the 13D/A filing but said it has not yet received the required notice about the nominations from Icahn Partners.

The company said its corporate governance committee is engaged in a process to recommend a slate for election at the annual meeting and is reviewing potential nominees suggested by shareholders as part of that process, including two individuals previously discussed with representatives of the Icahn funds.

Amylin is a biopharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.